Healthcare provider profile · identity verified

Danny Lock, MD

Family Practice · LA VERNE, CA · NPI 1144280348

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	696	202
Rosuvastatin Calcium	Rosuvastatin Calcium	517	160
Lisinopril	Lisinopril	406	115
Amlodipine Besylate	Amlodipine Besylate	306	89
Levothyroxine Sodium	Levothyroxine Sodium	284	74
Losartan Potassium	Losartan Potassium	264	81
Gabapentin	Gabapentin	210	49
Tamsulosin Hcl	Tamsulosin Hcl	197	60
Furosemide	Furosemide	190	45
Metformin Hcl	Metformin Hcl	174	59
Metoprolol Succinate	Metoprolol Succinate	172	48
Omeprazole	Omeprazole	163	50
Eliquis	Apixaban	160	32
Carvedilol	Carvedilol	152	39
Famotidine	Famotidine	127	45
Albuterol Sulfate Hfa	Albuterol Sulfate	126	45
Ezetimibe	Ezetimibe	110	38
Pantoprazole Sodium	Pantoprazole Sodium	102	34
Fluticasone Propionate	Fluticasone Propionate	96	39
Alendronate Sodium	Alendronate Sodium	95	26
Jardiance	Empagliflozin	94	27
Glipizide Er	Glipizide	92	28
Hydrochlorothiazide	Hydrochlorothiazide	91	25
Finasteride	Finasteride	84	27
Olmesartan Medoxomil	Olmesartan Medoxomil	83	21
Farxiga	Dapagliflozin Propanediol	74	13
Meloxicam	Meloxicam	71	15
Clopidogrel	Clopidogrel Bisulfate	69	19
Pravastatin Sodium	Pravastatin Sodium	69	18
Allopurinol	Allopurinol	67	18
Potassium Chloride	Potassium Chloride	67	21
Cephalexin	Cephalexin	65	33
Nifedipine Er	Nifedipine	64	16
Citalopram Hbr	Citalopram Hydrobromide	63	23
Pioglitazone Hcl	Pioglitazone Hcl	55	19
Tramadol Hcl	Tramadol Hcl	54	16
Metoprolol Tartrate	Metoprolol Tartrate	53	14
Xarelto	Rivaroxaban	52	suppressed
Chlorthalidone	Chlorthalidone	48	13
Diclofenac Sodium	Diclofenac Sodium	48	19
Ozempic	Semaglutide	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	45	suppressed
Ibuprofen	Ibuprofen	44	21
Trazodone Hcl	Trazodone Hcl	44	15
Benazepril Hcl	Benazepril Hcl	43	15
Entresto	Sacubitril/Valsartan	43	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	41	25
Sertraline Hcl	Sertraline Hcl	38	11
Doxazosin Mesylate	Doxazosin Mesylate	37	12
Prednisone	Prednisone	37	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Amiodarone Hcl	Amiodarone Hcl	32	suppressed
Glipizide	Glipizide	32	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Januvia	Sitagliptin Phosphate	32	suppressed
Mounjaro	Tirzepatide	32	suppressed
Telmisartan	Telmisartan	32	suppressed
Terazosin Hcl	Terazosin Hcl	31	suppressed
Sildenafil Citrate	Sildenafil Citrate	29	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Amoxicillin	Amoxicillin	27	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Valsartan	Valsartan	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Temazepam	Temazepam	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Baclofen	Baclofen	24	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	11
Mometasone Furoate	Mometasone Furoate	24	11
Felodipine Er	Felodipine	23	suppressed
Lansoprazole	Lansoprazole	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	16
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Lorazepam	Lorazepam	21	11
Myrbetriq	Mirabegron	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Atenolol	Atenolol	19	suppressed
Clobetasol Propionate	Clobetasol Propionate	19	suppressed
Hydrocortisone	Hydrocortisone	19	12
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Diltiazem Hcl	Diltiazem Hcl	18	suppressed
Mupirocin	Mupirocin	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Latanoprost	Latanoprost	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Lovastatin	Lovastatin	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Azithromycin	Azithromycin	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Selenium Sulfide	Selenium Sulfide	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error